Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) headquartered in Boston, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website paratekpharma.com
Earnings Expectation
Paratek Pharmaceuticals, Inc. clinical stage biopharma firm, is expected to report second quarter earnings results, before market open, on Monday 10th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.06 per share. Looking ahead, the full year loss are expected at $ 1.85 per share on the revenues of $ 81.16 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 75.00 million ~ $ 80.00 million
Click Here For More Historical Outlooks Of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
